AFFY:OTC-Affymax, Inc (USD)

COMMON STOCK | Biotechnology | OTC

Last Closing Price

USD 0.03

Change

0.00 (0.00)%

Market Cap

USD 2.94M

Volume

4.23K

Average Target Price

N/A
Average Analyst Rating

N/A

Fundamental Analysis

Verdict

About

Affymax, Inc. does not have significant operations. Previously, it was developing drugs to enhance the treatment of serious and often life-threatening conditions in the United States. The company was founded in 2001 and is based in New York, New York.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-11-26 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
NONOF Novo Nordisk A/S

N/A

USD156.63B 24.39 2.70
CMXHF CSL Limited

N/A

USD106.15B 45.96 27.25
CSLLY CSL Limited

N/A

USD103.11B 46.54 27.25
GNMSF Genmab A/S

N/A

USD23.61B 26.75 2.65
UCBJY UCB SA

N/A

USD20.50B 23.17 17.71
UCBJF UCB SA

N/A

USD20.40B 23.96 17.71
SBMFF Sino Biopharmaceutical Limited

N/A

USD20.37B 47.84 3.18
SBHMY Sino Biopharmaceutical Limited

N/A

USD18.81B 52.10 3.18
PPTDF PeptiDream Inc

N/A

USD5.83B 260.99 1.61
ABCZY Abcam plc

N/A

USD4.35B 236.08 106.86

ETFs Containing AFFY

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -13.33% N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return -13.33% N/A N/A N/A N/A
Trailing 12 Months  
Capital Gain 30.00% N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 30.00% N/A N/A N/A N/A
Trailing 5 Years  
Capital Gain -72.04% N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return -72.04% N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -12.34% N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return -12.34% N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 51.97% N/A N/A N/A N/A
Risk Adjusted Return -23.75% N/A N/A N/A N/A
Market Capitalization 2.94M N/A N/A N/A N/A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 0.96 N/A N/A N/A N/A
Price/Book Ratio 0.56 N/A N/A N/A N/A
Price / Cash Flow Ratio -0.04 N/A N/A N/A N/A
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity 111.59% N/A N/A N/A N/A
Return on Invested Capital -456.89% N/A N/A N/A N/A
Return on Assets -228.91% N/A N/A N/A N/A
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 2.35 N/A N/A N/A N/A
Short Percent 49.35% N/A N/A N/A N/A
Beta 2.39 N/A N/A N/A N/A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Negative cashflow

The company had negative total cash flow in the most recent four quarters.